Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-ready asset, and a Phase 2 asset
Two portfolio assets are now generating cash flows from commercial sales
Company expects at least one partner to file a New Drug Application in third quarter of 2023
https://finance.yahoo.com/news/xoma-reports-second-quarter-2023-113000980.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.